Background: Chronic spontaneous urticaria (CSU) can be debilitating, difficult to
| INTRODUCTION
Chronic spontaneous urticaria (CSU) (also called chronic idiopathic urticaria) 1 is characterized by the occurrence of urticaria for 6 weeks or longer without identifiable specific triggers. 2 The average duration of CSU is frequently reported as 5 years 3-5 but may be longer in more severe cases 3, 4 -specifically, in patients with concurrent angioedema, 4, 6, 7 CSU in combination with inducible urticaria, 4, 7 or a positive autologous serum skin test. 1, 8 The estimated point prevalence of CSU is approximately 0.5% to 1%. 9 Until omalizumab was approved in early 2014, H 1 -antihistamines were the only approved medication for CSU and were the mainstay of symptomatic treatment. However, over 60% of patients remain symptomatic despite treatment with second-generation H 1 -antihistamines at the licensed dose. 10 Available evidence indicates that all forms of chronic urticaria can substantially affect patients' quality of life (QoL), ability to perform daily tasks, and mental health. [11] [12] [13] [14] Patients with chronic urticaria (used as a proxy for CSU) experience substantial health-related quality of life (HRQoL) and productivity impairments and increased psychological comorbidities relative to patients without chronic urticaria. [15] [16] [17] Nevertheless, real-world research quantifying the humanistic and economic impact of diagnosed CSU is limited, and a number of unmet needs exist in this patient population, 9 particularly among those refractory to standard treatment.
The ASSURE-CSU (ASSessment of the Economic and Humanistic
Burden of Chronic Spontaneous/Idiopathic URticaria patiEnts) study sought to improve understanding of CSU and to explore the unmet needs of patients whose disease has persisted for longer than 12 months and is inadequately controlled by standard treatment.
Specifically, the main objectives of this study were to characterize, in this population, disease duration, disease activity, and treatment history, as well as to identify and quantify the humanistic, societal, and economic burden of CSU.
2 | ME TH ODS
| Study design and participants
The study design has previously been described in detail. 18 Briefly, this noninterventional, multinational, and multicenter study was conducted in Canada, France, Germany, Italy, Spain, the Netherlands, and the United Kingdom (UK). Recruitment of 700 patients was planned. Data collection occurred from October 2013 until May 2015, with each center recruiting over a 4-month period. Figure S1 describes the patient selection process. Eligible patients were adults with a clinician-confirmed diagnosis of CSU 19 who had received at least one treatment course with an H1-antihistamine and were symptomatic despite treatment. 18 The study was reviewed and exempted by the RTI International
Institutional Review Board and was reviewed and approved by the relevant national, local, and site-level ethics committees. The study was conducted in accordance with the Declaration of Helsinki; 20 all patients provided written informed consent.
| Study measures
The study included a 12-month retrospective medical record abstraction, a cross-sectional patient survey administered at enrollment, and a patient diary completed over an 8-day period after recruitment ( Figure 1 ). Both the survey [21] [22] [23] [24] [25] and the patient diary [26] [27] [28] included study-specific questions and validated PRO measures (Table S1 in Appendix S1).
Direct and indirect costs were estimated for each country. Direct costs included CSU-related treatments, physician visits, emergency department (ED) visits, and hospitalizations documented in medical records, as well as CSU-related alternative medicine, other out-ofpocket costs, and transportation reported in the patient survey. Indirect costs included the cost of patient-reported workdays missed and lost productivity due to CSU.
| Data analysis
Data analyses were descriptive. Data from all countries were pooled for all outcomes except for direct and indirect costs. With the exception of imputation of missing start dates for therapy data, no imputation of missing data was performed, and no formal hypothesis testing was conducted. Descriptive tables were generated overall and stratified by Urticaria Activity Score over 7 days, twice-daily assessment (UAS7) score bands. These score bands categorize the UAS7 into four levels of disease activity: UAS7=0-6 (urticaria-free or well-controlled urticaria activity), 7-15 (mild activity), 16-27 (moderate activity), and 28-42 (severe activity). 29, 30 Mean values, standard deviations (SDs), medians, and ranges were computed for continuous variables; counts were collected and percentages were computed for categorical variables. All analyses were performed using SAS version 9.3 or later (Cary, North Carolina, USA: SAS Institute, Inc.; 2011).
For the direct cost calculations, costing algorithms were used to assign 2014 unit costs from published sources in the respective country's currency to the resource utilization data. 31 Indirect costs for workdays missed and lost productivity due to CSU were calculated by the human capital approach using each country's specific average wage and hours worked. 32 Pooled cost calculations were not conducted. Country costs were converted to purchasing power parity dollars (PPP$) using published methodology and sources. 33 All cost calculations were performed using Microsoft Excel 2010.
3 | RESULTS
| Patient population
A total of 673 patients were enrolled in 64 recruiting centers, primarily hospital-based specialist centers ( Figure 3B ). The EQ-5D-3L domains for which patients most frequently reported moderate or extreme problems were pain/ discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) ( Figure 3C ). Across nearly all HRQoL domains, impact increased with increasing CSU activity.
| CSU-associated angioedema is a common and debilitating problem
According to medical records, 58.5% (394 of 673) patients were reported to have had CSU-associated angioedema, and 41.0% 
| CSU affects work performance and productivity
Of the 604 patients reporting, 341 (56.5%) indicated that they were currently employed. Among employed patients, the mean (SD) absenteeism, presenteeism, and overall work impairment were 6.1% (17.83%), 25.2% (25.78%), and 26.9% (27.53%), respectively, over the previous 7 days. Among the 329 employed patients responding, 72 (21.9%) had missed at least 1 hour of work in the past 7 days because of problems associated with CSU; among these, 45 patients (62.5%) missed up to 1 day of work and 27 (37.5%) missed more than 1 day in the past 7 days. The main reasons affecting capacity to work were itching (39.8%) and angioedema (28.2%).
Disease activity affected work performance, and greater disease activity had a greater negative productivity impact: mean (SD) overall work productivity loss was 11.9% (21.55%) among those with lowest disease activity and 43.6% (28.38%) among those with highest disease activity. Presenteeism (ie, impairment while at work) was the primary driver for overall work productivity loss, ranging from a mean (SD) of 9.8% (15.94%) among those with lowest disease activity to 40.4% (27.42%) among those with highest disease activity ( Figure S2 in Appendix S2). (Table S7 in Appendix S7).
T A B L E 1 Patient characteristics

| DISCUSSION
To our knowledge, the ASSURE-CSU study is the first international analysis of the burden of CSU inadequately controlled by standard treatment. We report novel findings for current treatment patterns, impact on HRQoL, and the economic burden to patients, healthcare systems, and society. A key strength is the use of a patient survey and retrospective medical record review to provide Table S4 in Appendix S4. b Ns in legend represents the total number of survey completers in each UAS7 score band. Some of these patients had insufficient data to calculate an overall score and/or individual domain scores.
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c Ns in legends represents the total number of survey completers in each UAS7 score band. Some of these patients had insufficient data to calculate domain scores. more comprehensive evidence than is captured using only administrative data sources (e.g., medical claims). As both disease activity and HRQoL were evaluated over a similar period, the impact of varying levels of disease activity on patients' lives was clarified.
Moreover, we identified significant humanistic and economic burdens relating to CSU that have not been reported previously. Nevertheless, estimates of disease burden from this study may be conservative, and the observed treatment patterns might not represent the general CSU population. Patients were recruited from urticaria specialty centers and, as such, were receiving expert care for CSU.
Most patients in ASSURE-CSU had moderate-to-severe physician-assessed disease activity at diagnosis, and patients experi- 
EQ-5D-3L domains
Urticaria Activity | 2011 the patient diary. However, treatment could be suboptimal and in fact was absent for some patients during the study period.
Patients not receiving treatment may have discontinued previous treatments owing to ineffectiveness or cost factors, among other reasons.
Angioedema was found to be more frequent than previously thought: Physicians reported that nearly 60% of patients with CSU experienced angioedema, and two-thirds of them had experienced it within the past 12 months. More patients than physicians reported angioedema during this time period and reported its considerable impact on emotional well-being, fatigue, and mood. Our findings suggest that angioedema plays a significant role in the burden of CSU, affecting every aspect of HRQoL and driving direct costs. Further analyses of ASSURE-CSU data are ongoing to examine the misalignment between physicians' and patients' reports and to better understand the impact of angioedema.
Mean DLQI scores in this study suggest that CSU has a moderate impact on patients' HRQoL, 35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic. 36 In addition,
HRQoL impairments correlated with disease activity, notably so in daily activity and sleep interference domains across measures. Particularly in patients with a UAS7 of 16 or greater, overall impact of CSU on usual activities represents a significant burden to themselves and to society.
Some notable differences were observed between patient and physician reporting, potentially suggesting that patients may not always communicate their urticaria symptoms to their physicians, in turn mitigating physicians' ability to treat effectively. Unanswered questions remain about patients' abilities to accurately identify or recall angioedema symptoms and physicians' likelihood of capturing these events in medical records. Discrepancies also existed between physicians' and patients' reports of resources used-specifically visits to other healthcare professionals and medications, particularly alternative therapies (eg, homeopathic treatments), that the patient was using. More research is needed to fully address these differences and provide education and resources to patients and providers alike.
ASSessment of the Economic and Humanistic Burden of Chronic
Spontaneous/Idiopathic URticaria patiEnts provides valuable insight into the economic burden of CSU. To our knowledge, only a US claims database analysis, 37 a small US single-center analysis, 38 and a cost-effectiveness analysis in France 39 have previously evaluated CSU-associated costs, and none is directly comparable with our study. Although previously thought to be infrequent, CSU-related ED visits in ASSURE-CSU were reported for 14% of patients, and hospitalizations were reported for 8% of patients. This is in contrast affected productivity, such that one in five patients took time off from work and one in four experienced reduced productivity at work. These findings are comparable with work productivity impairments in chronic urticaria [15] [16] [17] and in other dermatologic conditions, including atopic dermatitis, 40, 41 plaque psoriasis, 42 and severe psoriasis. 16, 43, 44 The reasons for ED visits and hospitalizations may center on patient and physician awareness and education. Depending on the healthcare system in a country, the use of this high-cost care could be due to an inaccessibility of primary-or secondary-care physicians for flare-ups and steroid prescriptions. Alternatively, patients who have been treated in the ED before may feel that it is where CSU should be treated, or they may receive secondary gain from this visit, such as sick leave. In certain circumstances, hospitalization may be used for observation or to manage angioedema when anaphylaxis is feared by inexperienced ED physicians or because of delays in specialist referral.
Treatment modalities reported included therapies recommended in the current guidelines during the study period. However, patients
were not always treated along formal guideline recommendations:
For example, sedating first-generation H 1 -antihistamines, intravenous immunoglobulin, and long-term oral corticosteroids were not uncommon. These results suggest that, at the time of study, some providers may have had insufficient resources or knowledge in treating patients with CSU. They may have resorted to trial-and-error approaches with therapies that carry significant side-effect risks and lack efficacy evidence, 2 particularly when treating patients refractory to standard licensed therapy. Moreover, the monoclonal antibody omalizumab was included in the urticaria treatment guidelines in While the study used a systematic patient selection method, a similar approach was not possible for physician and center selection due to the small number of specialist units for this population. Centers were selected to achieve variation in location, specialty, size, and type, but the resulting sample is not guaranteed to be representative of all centers and physicians treating patients with CSU. Likewise, inclusion criteria required patients to be symptomatic despite treatment and thus, the study does not reflect the entire population of patients with CSU.
Data and information about symptoms, HRQoL, and out-ofpocket expenses collected in the patient survey may have been subject to recall bias. The recall period for validated PROs varied from 7 days for the DLQI to 4 weeks for the AE-QoL and for the patient medical resource survey was limited to 3 months to minimize the potential for such bias. While there was some heterogeneity across countries, results were strikingly similar particularly with respect to HRQoL.
Additional research is needed to explore patient characteristics,
given that most patients in ASSURE-CSU were Caucasian and (consistent with previous findings 45, 46 ) female, as well as patterns relating to disease activity and duration of disease. Because of the inherent fluctuations in CSU activity, longer or repeated assessments would help confirm the results. The impact of CSU on work performance and productivity warrants additional evaluation. Our findings suggest that there may be inadequate knowledge among medical staff of the appropriate workup for CSU, and there is a need to increase awareness of the economic and humanistic impact of CSU among primary-and secondary-care providers and society in general.
| CONCLUSIONS
Chronic spontaneous urticaria is a chronic, disabling disease with little previous research that is challenging to treat adequately. The humanistic and economic burden of CSU has been underestimated. There is considerable delay in diagnosis and specialist referral, and there is inadequate knowledge among medical staff in primary and secondary care about CSU. Incorrect treatment patterns have been identified, and the high cost of unnecessary investigations and treatments is due to poor compliance with guidelines and best practices. Additional analyses should explore these findings in detail. To address unmet needs in CSU, it will be important to promote treatment guidelines and evidencebased practices among healthcare providers.
